Visceral Leishmaniasis
Conditions
Brief summary
This is a phase II/III open, comparative dose trial to find the lowest single dose of AmBisome for the treatment of primary, symptomatic visceral leishmaniasis(VL), in HIV negative patients. In this trial, the minimum effective dose will be determined in a sequential step, dose escalation design, which minimises the number of patients exposed to low, potentially inadequate doses and provides contemporaneous comparative data against the manufacturer's recommended dose schedule in this indication.
Interventions
DRUGLiposomal amphotericin B (Ambisome)
21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
Sponsors
Addis Ababa University
Drugs for Neglected Diseases
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
4 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male and female adults and children aged 4 years or older with no upper age limit (in accordance with manufacturer's instructions) * Acute, symptomatic, VL proven by parasitological examination of splenic aspirate (or bone marrow aspirate) with initial parasite index of at least 2+ * Haemoglobin \>4g/dL * Fever for more than 2 weeks * Living within reachable distance of the trial site to enable attendance for follow-up visits * Written informed consent to participate (for children, by parent or guardian) * HIV negative status
Exclusion criteria
* Patients 'in extremis' with signs/symptoms indicative of severe VL * Patients who have received any anti-leishmanial treatment within the last 6 months * Patients who have received any investigational (unlicensed) drugs during 6 months before recruitment * Known underlying chronic disease, such as severe cardiac, pulmonary, renal, or hepatic impairment. * Renal function tests (serum creatinine) outside the normal range * Liver function tests more than 3 times the normal range at study entry * Platelet count less than 40,000/ mm3 * Known alcohol abuse * Pregnancy or lactation * Concomitant acute drug usage for malaria and bacterial infection, pneumonia within last 7 days * Known hypersensitivity to AmBisome or amphotericin B * Any other condition which may invalidate the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary efficacy variable is parasitological clearance with no relapse at 6 months post treatment (ie definitive cure) assessed by clinical status and confirmed by splenic or bone marrow aspiration. | at 6 months post treatment |
Secondary
| Measure | Time frame |
|---|---|
| Parasitological clearance at day 30. | Day 30 |
Countries
Ethiopia, Sudan
Outcome results
None listed